Medtronic wins FDA clearance for LigaSure vessel sealer on Hugo surgical robot

Medtronic plc, the Galway, Ireland headquartered medical technology group, has spent years building a surgical robotics franchise around the Hugo robotic-assisted surgery system, a platform the company has positioned as a modular option for hospitals that want more than one robotic system available in the operating room. In the United States, that effort has moved deliberately rather than quickly. Hugo is cleared in the U.S. only for urologic surgical procedures, and Medtronic says the system is in commercial use at a growing number of U.S. health systems, while the company works to widen the label to general and gynecologic soft-tissue procedures. Outside the U.S., the picture is broader: Hugo has reached more than 35 countries and more than 50 different surgical procedures spanning urology, general surgery and gynecology.

The company announced on September 16, 2026 that the U.S. Food and Drug Administration has cleared the LigaSure RAS Maryland jaw device for use with the Hugo robotic-assisted surgery (RAS) system. PR Newswire reported on September 16 that the clearance expands the instruments available on Hugo and brings Medtronic's vessel-sealing technology to U.S. surgeons performing robotic-assisted procedures for the first time. The device is the first robotic-driven LigaSure instrument cleared for American robotic-assisted surgery, a milestone that links two of Medtronic's core surgical assets: the LigaSure sealing portfolio and the Hugo platform.

LigaSure is not a new name in operating rooms. The sealing technology underneath the new instrument has been used in more than 45 million procedures across 65 plus countries over the last two decades, according to Medtronic, largely in open and laparoscopic surgery. The LigaSure RAS Maryland instrument is designed exclusively for use with the Valleylab FT10 energy platform on the Hugo RAS system. It seals and cuts vessels, thick tissue and lymphatics up to and including 7 mm in diameter, sealing vessels in approximately 2 seconds while minimizing thermal spread to surrounding tissue, a specification that matters when surgeons operate close to delicate anatomy. The instrument reached Europe on Hugo in 2025 following CE Mark, and the U.S. clearance now carries that combination into American hospitals.

Dr. Matthew Kroh, chief medical officer within the Surgical business at Medtronic and a practicing surgeon, framed the clearance around surgeon confidence. "Vessel sealing sits at the center of how surgeons work through the most demanding moments of a procedure, and surgeons have trusted LigaSure to do it across open and laparoscopic surgery for decades," Kroh said. "Bringing that same performance to the Hugo RAS system in the U.S. means surgeons carry the confidence and control they already rely on into their robotic-assisted cases." OrthoSpineNews reported on September 16 that the same announcement, issued from Galway, Ireland, also pointed to Medtronic's wider footprint of 95,000 plus employees across 150 plus countries and technologies treating 70 health conditions.

Key Facts

StockTitan reported on September 16 that the LigaSure RAS Maryland device runs on the Valleylab FT10 energy platform and seals and cuts vessels, thick tissue and lymphatics up to and including 7 mm in diameter in approximately 2 seconds, with the aim of minimizing thermal spread. Those specifications match the ones Medtronic released in its own announcement, and they place the instrument in the same performance band as the LigaSure tools surgeons already use in laparoscopic work.

The clearance is the first time Medtronic's LigaSure sealing technology has been cleared for American robotic-assisted surgery. The company introduced the instrument on Hugo in Europe in 2025 following CE Mark, and it says the underlying technology has been used in more than 45 million procedures across 65 plus countries over the past two decades. Hugo itself has reached more than 35 countries and more than 50 surgical procedures outside the U.S.

Hugo's U.S. label remains narrower than its international label. Medtronic confirmed that Hugo is cleared in the U.S. only for urologic surgical procedures, and that it is continuing to progress plans to expand Hugo indications to a broad range of soft-tissue procedures, including general and gynecologic surgery. The company describes Hugo as being in commercial use at a growing number of U.S. health systems.

StockTitan also reported on September 16 that MDT shares declined 1.18 percent in that session, which it characterized as a mild negative market reaction, against a market capitalization of about $119.00 billion. The outlet listed no negatives for the clearance itself, a sign that the move was received as strategically useful rather than immediately transformative.

Analysis

The clearance is a genuine technical milestone, but it is not, on its own, a revenue unlock. Edgen reported on September 16 that the decision only expands Hugo's instrument tray, because Hugo remains cleared in the U.S. for urologic procedures and the commercial payoff depends on pending general and gynecologic indication expansions and on hospital adoption. What this really means is that Medtronic is assembling the components of a complete U.S. robotic surgery ecosystem, instrument by instrument, while it waits for the label that would let Hugo compete in the highest-volume soft-tissue categories.

The bigger picture here is about ecosystem depth, not a single device. Robotic surgery programs are built around instrument trays, and a robot is only as useful as the energy devices, staplers and sealing tools that can be docked onto it. LigaSure brings two decades of familiarity: Medtronic says the technology has been used in more than 45 million procedures across 65 plus countries. Surgeons who already trust the sealer in open and laparoscopic cases now have a reason to expect the same behavior inside a robotic case, which is a subtle but real adoption argument for Hugo.

There is also a sequencing story. Medtronic put LigaSure on Hugo in Europe in 2025, after CE Mark, and is now bringing the same instrument to the U.S. in 2026. That order lets the company gather European clinical experience before asking U.S. surgeons to change habits. At the same time, the urology-only U.S. label means the addressable U.S. market for this specific instrument is limited today. The market's muted response, with MDT down 1.18 percent on the day, suggests investors are reading the clearance exactly that way: strategically useful, financially modest for now.

A final judgment point concerns competition for scarce hospital capital budgets. Every robotic program competes for the same operating room time and the same capital committee approval, and Medtronic is trying to make Hugo's case on openness and on the strength of its existing energy portfolio rather than on raw robot placement alone. A first robotic LigaSure instrument in the U.S. strengthens that argument at the margin, but it does not by itself change the fact that Hugo's U.S. indication remains urology.

Why It Matters

For surgeons, the practical benefit is fewer compromises during a robotic case. A vessel sealer that seals and cuts vessels, thick tissue and lymphatics up to and including 7 mm in diameter in approximately 2 seconds, while limiting thermal spread, is the kind of tool that helps a procedure move without swapping platforms or instruments mid-case. Having that capability on Hugo means U.S. robotic surgeons can use a sealing technology that has been used in more than 45 million procedures worldwide.

For Medtronic, the clearance matters because surgical robotics is a long game. The company is based in Galway, Ireland, employs more than 95,000 people across more than 150 countries and says its technologies treat 70 health conditions. Hugo's international footprint of more than 35 countries and more than 50 procedures gives the platform a base of evidence and experience, and each cleared instrument adds another reason for a hospital to standardize on Hugo rather than treat it as a niche option.

For hospitals and patients, the near-term effect is incremental. Urologic procedures are the only U.S. indication today, so the new instrument will be used inside that boundary. The larger question is whether Medtronic can win the general and gynecologic indications it is pursuing, because those categories are where robotic surgery volumes are deepest and where a vessel sealer earns its keep most often.

Next Up

Medtronic says it is continuing to progress plans to expand Hugo indications to a broad range of soft-tissue procedures, including general and gynecologic surgery. Those submissions, and any subsequent FDA decisions, are the real commercial catalysts. In the meantime, watch how quickly U.S. health systems that already run Hugo add the LigaSure RAS Maryland instrument to their trays, and whether the company extends the robotic LigaSure line further.

Beyond the U.S., the European rollout that began in 2025 provides a template, and Hugo's reach across more than 35 countries and more than 50 procedures gives Medtronic room to keep adding instruments. The next chapter is less about one clearance than about whether the pieces, the robot, the energy platform and the instrument portfolio, finally add up to a broad soft-tissue franchise.